1500 E Medical Center Dr
Ann Arbor, MI 48109
Available to mentor
Dr. Yolanda Helfrich is a Professor of Dermatology and the residency program director of the Department of Dermatology at the University of Michigan Medical School. She serves as Chief of Medical Dermatology and provides medical dermatology services to patients of all ages within in our medical dermatology outpatient clinics.
Dr. Helfrich’s primary clinical focus is on medical dermatology. She has a special interest in rosacea, and has been invited to speak and write nationally about the pathogenesis and treatment of rosacea. She serves on the National Rosacea Society Medical Advisory Board. She also has a clinical specialization in the follow-up and diagnosis of high-risk skin cancer patients and runs a specialty clinic devoted to the care of patients with alopecia (hair loss).
Dr. Helfrich is a Michigan native. She grew up in Grayling and attended Grayling High School. She graduated with a B.A. in Latin and Ancient History from Swarthmore College in Pennsylvania. She subsequently attended medical school at the University of Michigan Medical School, graduating in 2001. Dr. Helfrich completed her internship in internal medicine and her residency in dermatology at the University of Michigan. She joined the faculty at the University of Michigan Department of Dermatology in 2005
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Throughout her career, Dr. Helfrich has had a strong interest in clinical research, and served as the Director of the Program for Clinical Research in Dermatology (PCRiD) in the department for 12 years. She has served as Primary Investigator on over 25 departmental and industry-sponsored clinical trials and research investigations of rosacea, atopic dermatitis, psoriasis, lichen planus, and other dermatologic conditions. She served on the Michigan Medicine Research Board of Directors Clinical Trials Subcommittee, with the key task of helping the institution create a unified clinical research enterprise, and subsequently served as one of the inaugural Medical Directors of the Neurosciences and Sensory Clinical Trials Support Unit.
-
Shao S, Sun Z, Chu M, Chen J, Cao T, Swindell WR, Bai Y, Li Q, Ma J, Zhu Z, Schuler A, Helfrich Y, Billi AC, Li Z, Hao J, Xiao C, Dang E, Gudjonsson JE, Wang G. Br J Dermatol, 2024 Mar 15; 190 (4): 536 - 548.Journal ArticleFormylpeptide receptor 1 contributes to epidermal barrier dysfunction-induced skin inflammation through NOD-like receptor C4-dependent keratinocyte activation.
DOI:10.1093/bjd/ljad455 PMID: 37979162 -
Lamberg O, Abdel-Mageed S, Olsen E, Guerrero G, Helfrich YR, Mervak JE. Arch Dermatol Res, 2024 Feb 24; 316 (3): 92Journal ArticlePatient perspectives on topical minoxidil for hair loss: a survey-based study from the University of Michigan Alopecia Clinic.
DOI:10.1007/s00403-024-02820-9 PMID: 38400906 -
Dirr MA, Ahmed A, Schlessinger DI, Haq M, Shi V, Koza E, Ma M, Christensen RE, Ibrahim SA, Schmitt J, Johannsen L, Asai Y, Baldwin HE, Berardesca E, Berman B, Vieira AC, Chien AL, Cohen DE, Del Rosso JQ, Dosal J, Drake LA, Feldman SR, Fleischer AB, Friedman A, Graber E, Harper JC, Helfrich YR, Jemec GB, Johnson SM, Katta R, Lio P, Maier LE, Martin G, Nagler AR, Neuhaus IM, Palamar M, Parish LC, Rosen T, Shumack SP, Solomon JA, Tanghetti EA, Webster GF, Weinkle A, Weiss JS, Wladis EJ, Maher IA, Sobanko JF, Cartee TV, Cahn BA, Alam M, IMPROVED-COS Rosacea Working Group , Kang BY, Iyengar S, Anvery N, Alpsoy E, Bewley A, Dessinioti C, Egeberg A, Engin B, Gollnick HPM, Ioannides D, Kim HS, Lazaridou E, Li J, Lim HG, Micali G, de Oliveira CMM, Noguera-Morel L, Parodi A, Reinholz M, Suh DH, Sun Q, van Zuuren EJ, Wollina U, Zhou Y, Zip C, Poon E, Pearlman R. JAMA Dermatol, 2024 Apr 24;Journal ArticleRosacea Core Domain Set for Clinical Trials and Practice: A Consensus Statement.
DOI:10.1001/jamadermatol.2024.0636 PMID: 38656294 -
Helfrich Y. 2023 Sep 11;PresentationLichen planopilaris and lichenoid variants of alopecia: diagnosis and management
-
Gradwohl K, Vaishampayan N, Eshaq M, Helfrich Y. J Am Acad Dermatol, 2023 Mar; 88 (3): 734 - 736.Journal ArticleE-visits for isotretinoin management have no effect on interruptions in care.
DOI:10.1016/j.jaad.2022.09.048 PMID: 36228938 -
Lamberg O, Strome A, Jones F, Mleczek J, Jarocki A, Troost JP, Helfrich Y. J Dermatolog Treat, 2023 Dec; 34 (1): 2213364Journal ArticleOcular side effects of systemic isotretinoin - a systematic review and summary of case reports.
DOI:10.1080/09546634.2023.2213364 PMID: 37248700 -
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N, LILAC Trial Investigators . N Engl J Med, 2022 Sep 8; 387 (10): 894 - 904.Journal ArticleTrial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
DOI:10.1056/NEJMoa2118025 PMID: 36069871 -
Billi A, Ma F, Gharaee-Kermani M, Xing X, Plazyo O, Schuler A, Wasikowski R, Swindell WR, Nakamura M, Helfrich Y, Kahlenberg J, Lee J, Tsoi LC, Voorhees J, Fisher GJ, Gudjonsson JE. Journal of Investigative Dermatology, 2022 May; 142 (8): s22 - s22.Proceeding / Abstract / PosterPervasive immune dysfunction characterizes photoaged skin
DOI:10.1016/j.jid.2022.05.135
